CORT Shares Plummet On FDA's Drug Rejection Letter Reveal - Here's What Retail Has To Say

(MENAFN - AsiaNet News) FDA refused to approve Corcept's Relacorilant for hypercortisolism in December, citing insufficient proof of effectiveness. The company CEO then said that the company ...